Roperty generated by the Barany laboratory; (ii) A Sponsored Analysis Agreement
Roperty generated by the Barany laboratory; (ii) A Sponsored Study Agreement among AcuamarkDx and Weill MCC950 manufacturer Cornell Medicine. M.D.B. and F.B. are shareholders in AcuamarkDx (which was not involved in the design and style in the study; collection, evaluation, and interpretation of data; and writing on the manuscript). Institutional Overview Board Statement: Not applicable. All datasets applied within the study are publicly accessible and downloaded from Gene Expression Omnibus and also the Cancer Dependency Map (DepMap) Project internet sites. Informed Consent Statement: Not applicable. See prior statements (concerning IRB). Information Availability Statement: The datasets used in the study have been downloaded from GEO and DepMap websites. Hyperlinks to the datasets are listed in Table S1. Conflicts of Interest: The authors declare no conflict of interest.Cancers 2021, 13,17 of
cancersErratumErratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Choice to Improve Efficacy of Cisplatin in Triple Unfavorable Breast Cancer and Defend PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13,Emma Rodriguez 1 , Guangsheng Pei two , Zhongming Zhao two , Sang T. Kim 3 , Alexis German 4 and Prema Robinson 1, Division of Infectious Diseases, Infection Control and Employee Wellness, The PF-06873600 In Vitro University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] Center for Precision Wellness, School of Biomedical Informatics, The University of Texas Well being Science Center at Houston, Houston, TX 77030, USA; [email protected] (G.P.); [email protected] (Z.Z.) Division of Basic Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] University of Houston, Houston, TX 77004, USA; [email protected] Correspondence: [email protected]; Tel.: +1-713-745-8346; Fax: +1-713-745-Citation: Rodriguez, E.; Pei, G.; Zhao, Z.; Kim, S.T.; German, A.; Robinson, P. Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Alternative to Improve Efficacy of Cisplatin in Triple Adverse Breast Cancer and Safeguard PC12 Cells against Cisplatin-Induced Oxidative Pressure and Apoptosis. Cancers 2021, 13, 3871. Cancers 2021, 13, 5178. https://doi.org/10.3390/ cancers13205178 Received: 7 October 2021 Accepted: 9 October 2021 Published: 15 OctoberOne contributor’s name was missing within the original version of your authorship from the paper [1]. This author is Zhongming Zhao, who really should be listed as the third author. He belongs towards the original affiliation 2 (Zhongming Zhao two ):Center for Precision Well being, College of Biomedical Informatics, The University of Texas Well being Science Center at Houston, Houston, TX 77030, USA The updated authorship is listed as beneath: Emma Rodriguez, Guangsheng Pei, Zhongming Zhao, Sang T. Kim, Alexis German and Prema Robinson The “Author Contributions” statement as a result really should be updated for the following version: Author Contributions: Conceptualization, P.R.; methodology, P.R., E.R., S.T.K., G.P., and Z.Z.; formal analyses, P.R., S.T.K., G.P., and Z.Z.; investigation, A.G.; original draft preparation, P.R.; evaluation and editing, P.R., E.R., S.T.K., and G.P. All authors have study and agreed for the published version with the manuscript. The authors have confirmed that the updated authorship meets the ICMJE criteria, the suggestions of which are followed by this journal. We apologize for this error and state that the scientific conclus.
